# Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE

Source: https://onco.cc/key-papers/paper-alexander-clin-cancer-res/  
OnCo record `paper-alexander-clin-cancer-res` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Paper cited by one trial page, indexed on Europe PMC as PubMed record 28814435 and published in Clinical Cancer Research; the citing page links this DOI, which is how the record was matched.

## Summary

Glioblastoma (GBM) is a deadly disease with few effective therapies. Although much has been learned about the molecular characteristics of the disease, this knowledge has not been translated into clinical improvements for patients. At the same time, many new therapies are being developed. Many of these therapies have potential biomarkers to identify responders. The result is an enormous amount of testable clinical questions that must be answered efficiently. The GBM Adaptive Global Innovative Learning Environment (GBM AGILE) is a novel, multi-arm, platform trial designed to address these challenges. It is the result of the collective work of over 130 oncologists, statisticians, pathologists, neurosurgeons, imagers, and translational and basic scientists from around the world. GBM AGILE is composed of two stages. The first stage is a Bayesian adaptively randomized screening stage to identify effective therapies based on impact on overall survival compared with a common control. This stage also finds the population in which the therapy shows the most promise based on clinical indication and biomarker status. Highly effective therapies transition in an inferentially seamless manner in the identified population to a second confirmatory stage. The second stage uses fixed randomization to confirm the findings from the first stage to support registration. Therapeutic arms with biomarkers may be added to the trial over time, while others complete testing. The design of GBM AGILE enables rapid clinical testing of new therapies and biomarkers to speed highly effective therapies to clinical practice. Clin Cancer Res; 24(4); 737-43. ©2017 AACR.

Indexed on Europe PMC as PubMed record 28814435 (DOI 10.1158/1078-0432.ccr-17-0764). Matched by DOI alone: one trial page cites this DOI among its external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: Clinical Cancer Research
- Year: 2018
- DOI: 10.1158/1078-0432.ccr-17-0764
- Authors: Alexander BM, Ba S, Berger MS, et al.
- What it means: One trial page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
- Caveats: Matched to the citing OnCo records by DOI alone; the summary reproduces the Europe PMC abstract and no figure has been verified against the full paper.

## Sources

- Clin Cancer Res 2018: https://doi.org/10.1158/1078-0432.ccr-17-0764
- PubMed: https://pubmed.ncbi.nlm.nih.gov/28814435/
- Europe PMC: https://europepmc.org/article/MED/28814435

## Connected records

- trials: [GBM AGILE](https://onco.cc/trials/gbm-agile/)
- journals: [Clinical Cancer Research](https://onco.cc/journals/clinical-cancer-research/)

---
JSON: https://onco.cc/api/v1/entities/paper-alexander-clin-cancer-res.json